The importance of individualised approach to the treatment of T2DM

CPD Questionnaire

EARN FREE CPD POINTS

Complete, scan and email to **cpd@denovomedica.com**. Alternatively, you can complete this questionnaire online at **www.denovomedica.com**. Fill in your details using **clear block letters** and mark the answers with a tick (✓).

I agree that my CPD-accredited certificate will be forwarded to my e-mail address. (Online) _____

(Signature of healthcare professional)

First Name		**Profession**	
Surname		**Telephone**	
HPC No.		**City**	
E-mail			

1. In the DISCOVER study programme, what was the average HbA_{1c} in 40 % of South African patients when a second therapeutic agent was added to metformin?

- ☐ **A** 8 %
- ☐ **B** 9 %
- ☐ **C** ≥ 9 %

2. Lack of progression of T2DM therapy is likely due to:

- ☐ **A** Patient concerns and fears
- ☐ **B** Clinical inertia
- ☐ **C** Lack of persuasive data applicable to primary care practice
- ☐ **D** All of the above

3. Primary care practice trials need to:

- ☐ **A** Include a broad set of patients
- ☐ **B** Not put too heavy a support role on the practices
- ☐ **C** Be multi-centred, randomised, but not necessarily double-blind
- ☐ **D** All of the above

4. The LIRA-PRIME trial was conducted in multiple primary care practices.

- ☐ **A** True
- ☐ **B** False

5. On top of adequate maximum tolerated dose of metformin, which of the following agents were not included in LIRA-PRIME as commonly used in patient-centred care?

- ☐ **A** SGLT-2 inhibitors
- ☐ **B** GLP-1 RAs (liraglutide)
- ☐ **C** DPP-4 inhibitors
- ☐ **D** Sulphonylureas
- ☐ **E** Insulin

6. The HbA_{1c} of patients included in the LIRA-PRIME trial was:

- ☐ **A** < 7.5 %
- ☐ **B** 7.5-8.5 %
- ☐ **C** 7.5-9 %

7. In the LIRA-PRIME trial the primary endpoint of inadequate control (> 7 % at two consecutive visits) was how long in the OAD group?

- ☐ **A** 55 weeks
- ☐ **B** 65 weeks
- ☐ **C** 75 weeks

8. In the LIRA-PRIME trial, liraglutide maintained control (< 7 % for two visits) for:

- ☐ **A** 80 weeks
- ☐ **B** 90 weeks
- ☐ **C** > 100 weeks

9. How many patients were treated with liraglutide?

- ☐ **A** 487 patients
- ☐ **B** 996 patients
- ☐ **C** 1 996 patients

10. Premature treatment discontinuation occurred later in patients treated with liraglutide versus any OAD.

- ☐ **A** True
- ☐ **B** False

© 2020 deNovo Medica